Effect of brimonidine on retinal blood flow autoregulation in primary open-angle glaucoma.

J Ocul Pharmacol Ther

Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.

Published: August 2011

Purpose: To determine whether topically applied brimonidine affects the retinal hemodynamic autoregulatory response to posture change in patients with normal tension glaucoma.

Methods: Six patients with normal tension glaucoma (primary open-angle glaucoma and maximum untreated intraocular pressure <22 mmHg) in each eye were studied. We retrospectively reviewed retinal hemodynamic data acquired when the patients were off and on treatment with brimonidine 0.15% (twice a day, both eyes) during the course of their care. At each testing session, vessel diameter and blood speed at the same site along the inferior temporal retinal artery of 1 eye were measured while sitting, while reclining for 30 min, and again while sitting using a retinal laser Doppler instrument. Blood flow was computed automatically. Brachial artery blood pressure and heart rate were also measured. The Wilcoxon signed rank test was used to assess the statistical significance of the differences in each measured parameter while subjects were on and off brimonidine.

Results: Off brimonidine, the mean blood flow rate increased by 68.0%±34.3% (range: +17% to +108%) after 30 min in reclined posture compared to baseline-seated measures. On brimonidine, the mean blood flow rate increased by 8.9%±16.8% (range: -9.7 to +28.0%) after 30 min in reclined posture compared to baseline-seated measures. The difference in the posture-induced changes for blood flow rate while on brimonidine compared to off brimonidine was statistically significant (P=0.027).

Conclusions: Off brimonidine, the patients exhibited marked increases in retinal blood flow while reclining. On brimonidine, the hemodynamic changes were consistent with normal autoregulatory control of retinal blood flow.

Download full-text PDF

Source
http://dx.doi.org/10.1089/jop.2011.0014DOI Listing

Publication Analysis

Top Keywords

brimonidine retinal
8
primary open-angle
8
open-angle glaucoma
8
patients normal
8
normal tension
8
retinal blood
4
blood flow
4
flow autoregulation
4
autoregulation primary
4
glaucoma purpose
4

Similar Publications

Introduction: Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents are a primary management option for retinal diseases. Acute elevation of intraocular pressure (IOP) is a complication associated with these injections that should be considered. This study investigated and compared the prophylactic effects of fixed combination anti-glaucoma medication on IOP spikes following intravitreal anti-VEGF injections.

View Article and Find Full Text PDF

Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.

Pharmaceuticals (Basel)

September 2024

Department of Ophthalmology, Wan Fang Hospital, Taipei Medical University, Taipei 110301, Taiwan.

Article Synopsis
  • * The review emphasizes the importance of neuroprotective strategies beyond just managing intraocular pressure, discussing both pharmacological options and advanced technologies that aim to protect RGCs and the optic nerve.
  • * Promising treatments include various drugs with neuroprotective potential, along with innovative approaches like stem cell and gene therapy, but further research and clinical trials are needed to validate their effectiveness in managing glaucoma.
View Article and Find Full Text PDF
Article Synopsis
  • This study evaluates the effects of brimonidine on visual functions, specifically contrast sensitivity in patients with acute optic neuritis.
  • Conducted as a randomized clinical trial with 60 participants, it compared the outcomes of those treated with brimonidine to a control group receiving synthetic tears over three months.
  • Results showed significant improvements in contrast sensitivity and visual acuity for the brimonidine group, indicating its potential neuroprotective benefits for retinal ganglion cell function.
View Article and Find Full Text PDF

The potential of brimonidine for myopia treatment: Targeting MMP-2 to regulate choroidal thickness and control eye growth.

Heliyon

September 2024

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.

Drug treatment studies are a focal point for identifying novel approaches to reduce myopia progression through basic science research. Here, we investigated the effects of various brimonidine administration routes and concentrations on form-deprivation myopia (FDM) progression, matrix metalloproteinase-2 (MMP-2), and collagen alpha1 chain of type I (COL1A1) expression in the retinal pigment epithelial (RPE)-choroid complex and sclera of guinea pigs. They demonstrate that brimonidine has the capacity to impede choroidal thinning induced by FDM, potentially through the induction of choroidal vasodilation.

View Article and Find Full Text PDF
Article Synopsis
  • - Glaucoma, a condition that damages retinal ganglion cells (RGC), was studied to evaluate the neuroprotective effects of brimonidine, which can lower intraocular pressure and potentially protect these cells.
  • - In the experiment, 41 mice had their optic nerves crushed and were divided into three groups receiving different treatments: saline, topical brimonidine, or a combination of topical and intraperitoneal (IP) brimonidine injections.
  • - Results showed that mice receiving both topical and IP brimonidine had significantly higher RGC survival rates compared to those receiving only saline or just topical brimonidine.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!